• 中国科学论文统计源期刊
  • 中国科技核心期刊
  • 美国化学文摘(CA)来源期刊
  • 日本科学技术振兴机构数据库(JST)

JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2026, Vol. 28 ›› Issue (5): 717-725.DOI: 10.3969/j.issn.1671-2587.2026.05.008

Previous Articles     Next Articles

The Influence of Preparation Methods on the Efficacy and Safety of Recombinant Apheresis Platelet Transfusion

ZHANG Li1, YI Hai2, MA Lei2, GAN Xinyu1, LIU Liping1, QI Yu1, TAN Qiang1, LI Huan1, REN Lina1, PENG Tao1   

  1. 1Department of Blood Transfusion, Chengdu 610083;
    2Department of Hematology, The General Hospital of Western Theater Command, Chengdu 610083
  • Received:2026-09-18 Revised:2026-10-08 Online:2026-10-20 Published:2026-11-11

Abstract: Objective This study aims to investigate the impact of two distinct preparation methods on the efficacy and safety of recombinant apheresis platelet transfusion, thereby providing empirical data to support its clinical application. Methods A prospective study was conducted involving 104 patients diagnosed with hematological disorders who had clear indications for platelet transfusion. Recombinant apheresis platelets were administered in cases where ABO-compatible platelets were unavailable. Based on the preparation method, the recombinant apheresis platelets were categorized into two groups: the centrifugation group and the apheresis group. The efficacy and safety of transfusions were subsequently compared between two groups. Results A total of 266 recombinant apheresis platelet transfusions were administered to the 104 patients. The centrifugation group enrolled 157 transfusions, while the apheresis group enrolled 109 transfusions. The comparison between the centrifugation and apheresis groups revealed the following: the average volume per single infusion was 0.98±0.08 for the centrifugation group and 0.96±0.09 for the apheresis group. The 12-hour post-transfusion platelet count increment was 9.5 (2, 18)×109/L for the centrifugation group and 9 (3, 17)×109/L for the apheresis group. In a comparative analysis of the two groups, the 12-hour Corrected Count Increment (CCI) was 6.08 (95%CI: 1.45, 12.19) versus 6.02 (95%CI: 1.19, 11.81), with infusion efficiencies of 57.32% and 64.22%, respectively. The subsequent platelet infusion intervals were 50.75 hours (95%CI: 24.88, 95.53) compared to 49.3 hours (95%CI: 26.58, 101.35). The rate of infusion-related adverse reactions was 0% in one group versus 0.92% in the other, with no statistically significant difference observed between the groups (P>0.05). However, the incidence of adverse events was higher in the centrifugation group at 4.46% compared to 0% in the apheresis group. The interval between platelet collection and transfusion was 2 days (range: 1-3 days) longer in the centrifugation group compared to 0 days (range: 0-1 day) in the apheresis group. The waiting time for platelet transfusion was reduced by 6.07 hours (95%CI: 3.55, 9.45) in the centrifugation group compared to 8.35 hours (95%CI: 4.99, 10.14) in the apheresis group. The number of recombinant apheresis platelet transfusions during hospitalization was 1 (range: 1-3) in the centrifugation group, which was higher than 1 (range: 1-2) in the apheresis group. Additionally, the total volume of platelet transfusion treatment during hospitalization was 7.80 units (95%CI: 4.00, 10.60) in the centrifugation group, exceeding the 6.00 units (95%CI: 3.6, 8.8) in the apheresis group.The regression analysis and mediation analysis indicated that there was no statistically significant difference in infusion efficacy [Odds Ratio (OR) 1.03—1.34, P>0.05] and safety (OR 1.99—4.35, P>0.05) between the two preparation methods. Conclusion Recombinant apheresis plateletsprepared through either centrifugation or apheresis are suitable for clinical infusion in patients with hematological disorders when ABO identical platelet is deficient. In practical applications, considerations such as current platelet inventory, infusion time constraints, patient blood type, donor blood type and quantity should be taken into account.

Key words: Recombinant apheresis platelets, Transfusion efficacy, Adverse event, Adverse transfusion reactions, Methods of preparation

CLC Number: